Bernhard J Hering1, Cassandra M Ballou2, Melena D Bellin3, Elizabeth H Payne4, Fouad Kandeel5, Piotr Witkowski6, Rodolfo Alejandro7, Michael R Rickels8, Franca B Barton4. 1. Schulze Diabetes Institute and Department of Surgery, University of Minnesota, Minneapolis, MN, USA. bhering@umn.edu. 2. The EMMES Company, LLC, Rockville, MD, USA. cballou@emmes.com. 3. Schulze Diabetes Institute and Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA. 4. The EMMES Company, LLC, Rockville, MD, USA. 5. Department of Clinical Diabetes, Endocrinology & Metabolism, City of Hope, Duarte, CA, USA. 6. Pancreatic and Islet Transplant Program, Transplantation Institute, University of Chicago, Chicago, IL, USA. 7. Diabetes Research Institute and Department of Medicine, University of Miami, Miami, FL, USA. 8. Institute for Diabetes, Obesity & Metabolism and Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Abstract
AIMS/HYPOTHESIS: Islet transplantation has been studied in small cohorts of recipients with type 1 diabetes complicated by severe hypoglycaemic events (SHEs). We determined factors associated with favourable outcomes in a large cohort of recipients reported to the Collaborative Islet Transplant Registry (CITR). METHODS: In 398 non-uraemic islet transplant alone (ITA) recipients with type 1 diabetes and SHEs, transplanted between 1999 and 2015 and with at least 1 year follow-up, we analysed specified favourable outcomes against each of all available characteristics of pancreas donors, islet grafts, recipients and immunosuppressive regimens, as well as immunosuppression and procedure-related serious adverse events (SAEs). RESULTS: Four factors were associated with the highest rates of favourable outcomes: recipient age ≥35 years; total infused islets ≥325,000 islet equivalents; induction immunosuppression with T cell depletion and/or TNF-α inhibition; and maintenance with both mechanistic target of rapamycin (mTOR) and calcineurin inhibitors. At 5 years after the last islet infusion, of the recipients meeting these four common favourable factors (4CFF; N=126), 95% were free of SHEs, 76% had HbA1c <53 mmol/mol (7.0%), 73% had HbA1c <53 mmol/mol (7.0%) and absence of SHEs, and 53% were insulin independent, significantly higher rates than in the remaining recipients (<4CFF; N=272). The incidence of procedural and immunosuppression-related SAEs per recipient that resulted in sequelae, disability or death was low in both the 4CFF (0.056 per person) and <4CFF (0.074 per person) groups. CONCLUSIONS/ INTERPRETATION: In recipients with type 1 diabetes complicated by SHEs, islet transplantation meeting 4CFF protected 95% from SHEs at 5 years after the last islet infusion and exerted a large and significant benefit on glycaemic control, with an acceptable safety profile for this subgroup of type 1 diabetes.
AIMS/HYPOTHESIS: Islet transplantation has been studied in small cohorts of recipients with type 1 diabetes complicated by severe hypoglycaemic events (SHEs). We determined factors associated with favourable outcomes in a large cohort of recipients reported to the Collaborative Islet Transplant Registry (CITR). METHODS: In 398 non-uraemic islet transplant alone (ITA) recipients with type 1 diabetes and SHEs, transplanted between 1999 and 2015 and with at least 1 year follow-up, we analysed specified favourable outcomes against each of all available characteristics of pancreas donors, islet grafts, recipients and immunosuppressive regimens, as well as immunosuppression and procedure-related serious adverse events (SAEs). RESULTS: Four factors were associated with the highest rates of favourable outcomes: recipient age ≥35 years; total infused islets ≥325,000 islet equivalents; induction immunosuppression with T cell depletion and/or TNF-α inhibition; and maintenance with both mechanistic target of rapamycin (mTOR) and calcineurin inhibitors. At 5 years after the last islet infusion, of the recipients meeting these four common favourable factors (4CFF; N=126), 95% were free of SHEs, 76% had HbA1c <53 mmol/mol (7.0%), 73% had HbA1c <53 mmol/mol (7.0%) and absence of SHEs, and 53% were insulin independent, significantly higher rates than in the remaining recipients (<4CFF; N=272). The incidence of procedural and immunosuppression-related SAEs per recipient that resulted in sequelae, disability or death was low in both the 4CFF (0.056 per person) and <4CFF (0.074 per person) groups. CONCLUSIONS/ INTERPRETATION: In recipients with type 1 diabetes complicated by SHEs, islet transplantation meeting 4CFF protected 95% from SHEs at 5 years after the last islet infusion and exerted a large and significant benefit on glycaemic control, with an acceptable safety profile for this subgroup of type 1 diabetes.
Authors: Bernhard J Hering; Raja Kandaswamy; Jeffrey D Ansite; Peter M Eckman; Masahiko Nakano; Toshiya Sawada; Ippei Matsumoto; Sung-Hee Ihm; Hui-Jian Zhang; Jamen Parkey; David W Hunter; David E R Sutherland Journal: JAMA Date: 2005-02-16 Impact factor: 56.272
Authors: Philipp A Gerber; Rebecca Locher; Richard A Zuellig; Oliver Tschopp; Evelyne Ajdler-Schaeffler; Philipp Kron; Christian Oberkofler; Michael Brändle; Giatgen A Spinas; Roger Lehmann Journal: Transplantation Date: 2015-10 Impact factor: 4.939
Authors: A M Shapiro; J R Lakey; E A Ryan; G S Korbutt; E Toth; G L Warnock; N M Kneteman; R V Rajotte Journal: N Engl J Med Date: 2000-07-27 Impact factor: 91.245
Authors: A M James Shapiro; Camillo Ricordi; Bernhard J Hering; Hugh Auchincloss; Robert Lindblad; R Paul Robertson; Antonio Secchi; Mathias D Brendel; Thierry Berney; Daniel C Brennan; Enrico Cagliero; Rodolfo Alejandro; Edmond A Ryan; Barbara DiMercurio; Philippe Morel; Kenneth S Polonsky; Jo-Anna Reems; Reinhard G Bretzel; Federico Bertuzzi; Tatiana Froud; Raja Kandaswamy; David E R Sutherland; George Eisenbarth; Miriam Segal; Jutta Preiksaitis; Gregory S Korbutt; Franca B Barton; Lisa Viviano; Vicki Seyfert-Margolis; Jeffrey Bluestone; Jonathan R T Lakey Journal: N Engl J Med Date: 2006-09-28 Impact factor: 91.245
Authors: Bernhard J Hering; William R Clarke; Nancy D Bridges; Thomas L Eggerman; Rodolfo Alejandro; Melena D Bellin; Kathryn Chaloner; Christine W Czarniecki; Julia S Goldstein; Lawrence G Hunsicker; Dixon B Kaufman; Olle Korsgren; Christian P Larsen; Xunrong Luo; James F Markmann; Ali Naji; Jose Oberholzer; Andrew M Posselt; Michael R Rickels; Camillo Ricordi; Mark A Robien; Peter A Senior; A M James Shapiro; Peter G Stock; Nicole A Turgeon Journal: Diabetes Care Date: 2016-04-18 Impact factor: 19.112
Authors: D W Scharp; P E Lacy; J V Santiago; C S McCullough; L G Weide; P J Boyle; L Falqui; P Marchetti; C Ricordi; R L Gingerich Journal: Transplantation Date: 1991-01 Impact factor: 4.939
Authors: P J O'Connell; D J Holmes-Walker; D Goodman; W J Hawthorne; T Loudovaris; J E Gunton; H E Thomas; S T Grey; C J Drogemuller; G M Ward; D J Torpy; P T Coates; T W Kay Journal: Am J Transplant Date: 2013-05-13 Impact factor: 8.086
Authors: A M Brooks; N Walker; A Aldibbiat; S Hughes; G Jones; J de Havilland; P Choudhary; G C Huang; N Parrott; N W A McGowan; J Casey; L Mumford; P Barker; K Burling; R Hovorka; M Walker; R M Smith; S Forbes; M K Rutter; S Amiel; M J Rosenthal; P Johnson; J A M Shaw Journal: Am J Transplant Date: 2013-10-01 Impact factor: 8.086